Published in J Intensive Care Med on June 09, 2008
Propylene glycol toxicity in children. J Pediatr Pharmacol Ther (2015) 1.03
Development and Evaluation of a Guideline for Monitoring Propylene Glycol Toxicity in Pediatric Intensive Care Unit Patients Receiving Continuous Infusion Lorazepam. J Pediatr Pharmacol Ther (2015) 0.83
Dexmedetomidine sedation in ICU. Korean J Anesthesiol (2012) 0.78
Trimethoprim/Sulfamethoxazole-Induced Severe Lactic Acidosis: A Case Report and Review of the Literature. Medicine (Baltimore) (2016) 0.78
Biochemical tolerance during low dose propylene glycol exposure in neonates: A formulation-controlled evaluation. Daru (2012) 0.77
Propylene Glycol Toxicity in Adolescent with Refractory Myoclonic Status Epilepticus. Case Rep Pediatr (2017) 0.75
Propylene glycol accumulation during continuous-infusion lorazepam in critically ill patients. J Intensive Care Med (2008) 0.75
Status Epilepticus due to Intraperitoneal Injection of Vehicle Containing Propylene Glycol in Sprague Dawley Rats. Vet Med Int (2017) 0.75
Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol (2004) 6.65
Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis (2006) 5.34
Accessory gene regulator group II polymorphism in methicillin-resistant Staphylococcus aureus is predictive of failure of vancomycin therapy. Clin Infect Dis (2004) 4.29
Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections. Clin Pharmacokinet (2004) 3.92
Recommendations for end-of-life care in the intensive care unit: a consensus statement by the American College [corrected] of Critical Care Medicine. Crit Care Med (2008) 3.85
Population pharmacokinetics of intravenous polymyxin B in critically ill patients: implications for selection of dosage regimens. Clin Infect Dis (2013) 3.49
Vancomycin in vitro bactericidal activity and its relationship to efficacy in clearance of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother (2007) 2.42
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 1: In vitro and animal models. Ann Pharmacother (2003) 2.30
Genetic deletion of myostatin from the heart prevents skeletal muscle atrophy in heart failure. Circulation (2010) 2.23
Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection. Antimicrob Agents Chemother (2007) 1.91
Evolutionary strata on the X chromosomes of the dioecious plant Silene latifolia: evidence from new sex-linked genes. Genetics (2007) 1.88
Transcriptional and post-transcriptional impact of toxic RNA in myotonic dystrophy. Hum Mol Genet (2009) 1.80
Fluoroquinolone AUIC break points and the link to bacterial killing rates. Part 2: human trials. Ann Pharmacother (2003) 1.74
Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother (2013) 1.74
Clinical pharmacodynamics of linezolid in seriously ill patients treated in a compassionate use programme. Clin Pharmacokinet (2003) 1.70
Microbiological effects of prior vancomycin use in patients with methicillin-resistant Staphylococcus aureus bacteraemia. J Antimicrob Chemother (2007) 1.61
Resurgence of colistin: a review of resistance, toxicity, pharmacodynamics, and dosing. Pharmacotherapy (2010) 1.59
Pharmacokinetics of polymyxin B in patients on continuous venovenous haemodialysis. J Antimicrob Chemother (2012) 1.59
Guidelines for intensive care unit design. Crit Care Med (2012) 1.51
Population pharmacokinetics of linezolid in patients treated in a compassionate-use program. Antimicrob Agents Chemother (2003) 1.49
Attenuation of colistin bactericidal activity by high inoculum of Pseudomonas aeruginosa characterized by a new mechanism-based population pharmacodynamic model. Antimicrob Agents Chemother (2010) 1.44
Predictive value of sputum gram stain for the determination of appropriate antibiotic therapy in ventilator-associated pneumonia. J Trauma (2007) 1.42
U.S. Food and Drug Administration approval summary: brentuximab vedotin for the treatment of relapsed Hodgkin lymphoma or relapsed systemic anaplastic large-cell lymphoma. Clin Cancer Res (2012) 1.41
Oral administration of fomepizole produces similar blood levels as identical intravenous dose. Clin Toxicol (Phila) (2008) 1.40
Application of an in vitro infection model and simulation for reevaluation of fluoroquinolone breakpoints for Salmonella enterica serotype typhi. Antimicrob Agents Chemother (2005) 1.35
Statistical methods and microarray data. Nat Biotechnol (2007) 1.35
Attenuated vancomycin bactericidal activity against Staphylococcus aureus hemB mutants expressing the small-colony-variant phenotype. Antimicrob Agents Chemother (2008) 1.33
Clinically relevant plasma concentrations of colistin in combination with imipenem enhance pharmacodynamic activity against multidrug-resistant Pseudomonas aeruginosa at multiple inocula. Antimicrob Agents Chemother (2011) 1.32
Pharmacokinetic/pharmacodynamic investigation of colistin against Pseudomonas aeruginosa using an in vitro model. Antimicrob Agents Chemother (2010) 1.31
U.s. Food and Drug Administration approval: carfilzomib for the treatment of multiple myeloma. Clin Cancer Res (2013) 1.27
Synergistic killing of multidrug-resistant Pseudomonas aeruginosa at multiple inocula by colistin combined with doripenem in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2011) 1.26
Development and qualification of a pharmacodynamic model for the pronounced inoculum effect of ceftazidime against Pseudomonas aeruginosa. Antimicrob Agents Chemother (2008) 1.26
The combination of colistin and doripenem is synergistic against Klebsiella pneumoniae at multiple inocula and suppresses colistin resistance in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2012) 1.25
Novel pharmacokinetic-pharmacodynamic model for prediction of outcomes with an extended-release formulation of ciprofloxacin. Antimicrob Agents Chemother (2004) 1.25
The efficacy and safety of linezolid as treatment for Staphylococcus aureus infections in compassionate use patients who are intolerant of, or who have failed to respond to, vancomycin. J Antimicrob Chemother (2002) 1.18
Pharmacodynamics of vancomycin at simulated epithelial lining fluid concentrations against methicillin-resistant Staphylococcus aureus (MRSA): implications for dosing in MRSA pneumonia. Antimicrob Agents Chemother (2009) 1.17
Population pharmacokinetics of oseltamivir: pediatrics through geriatrics. Antimicrob Agents Chemother (2013) 1.17
Pharmacological basis of β-lactamase inhibitor therapeutics: tazobactam in combination with Ceftolozane. Antimicrob Agents Chemother (2013) 1.13
Pharmacological and patient-specific response determinants in patients with hospital-acquired pneumonia treated with tigecycline. Antimicrob Agents Chemother (2011) 1.12
Hyperammonemia in cirrhosis induces transcriptional regulation of myostatin by an NF-κB-mediated mechanism. Proc Natl Acad Sci U S A (2013) 1.11
Oritavancin population pharmacokinetics in healthy subjects and patients with complicated skin and skin structure infections or bacteremia. Antimicrob Agents Chemother (2009) 1.11
Factors influencing time to vancomycin-induced clearance of nonendocarditis methicillin-resistant Staphylococcus aureus bacteremia: role of platelet microbicidal protein killing and agr genotypes. J Infect Dis (2010) 1.07
Tigecycline population pharmacokinetics in patients with community- or hospital-acquired pneumonia. Antimicrob Agents Chemother (2010) 1.07
High DNA sequence diversity in pericentromeric genes of the plant Arabidopsis lyrata. Genetics (2008) 1.07
Vancomycin AUC24/MIC ratio in patients with complicated bacteremia and infective endocarditis due to methicillin-resistant Staphylococcus aureus and its association with attributable mortality during hospitalization. Antimicrob Agents Chemother (2011) 1.07
Relevance of pharmacokinetic and pharmacodynamic modeling to clinical care of critically ill patients. Curr Pharm Biotechnol (2011) 1.05
Interdisciplinary patient care in the intensive care unit: focus on the pharmacist. Pharmacotherapy (2011) 1.02
The utility of acute physiology and chronic health evaluation II scores for prediction of mortality among intensive care unit (ICU) and non-ICU patients with methicillin-resistant Staphylococcus aureus bacteremia. Infect Control Hosp Epidemiol (2012) 1.02
Relationship between ceftolozane-tazobactam exposure and drug resistance amplification in a hollow-fiber infection model. Antimicrob Agents Chemother (2013) 1.01
Expansion of the pseudo-autosomal region and ongoing recombination suppression in the Silene latifolia sex chromosomes. Genetics (2013) 1.01
Relationships between patient- and institution-specific variables and decreased antimicrobial susceptibility of Gram-negative pathogens. Clin Infect Dis (2003) 1.01
New dosing strategies for an old antibiotic: pharmacodynamics of front-loaded regimens of colistin at simulated pharmacokinetics in patients with kidney or liver disease. Antimicrob Agents Chemother (2013) 1.01
Nucleotide diversity in Silene latifolia autosomal and sex-linked genes. Proc Biol Sci (2010) 1.01
Synergistic activity of colistin and rifampin combination against multidrug-resistant Acinetobacter baumannii in an in vitro pharmacokinetic/pharmacodynamic model. Antimicrob Agents Chemother (2013) 0.99
Grip force, EDL contractile properties, and voluntary wheel running after postdevelopmental myostatin depletion in mice. J Appl Physiol (1985) (2010) 0.99
Centromere locations and associated chromosome rearrangements in Arabidopsis lyrata and A. thaliana. Genetics (2006) 0.97
Pharmacist-managed antimicrobial stewardship program for patients discharged from the emergency department. J Pharm Pract (2011) 0.96
Comparative gene mapping in Arabidopsis lyrata chromosomes 6 and 7 and A. thaliana chromosome IV: evolutionary history, rearrangements and local recombination rates. Genet Res (2006) 0.96
Application of pharmacokinetic-pharmacodynamic modeling and the justification of a novel fusidic acid dosing regimen: raising Lazarus from the dead. Clin Infect Dis (2011) 0.96
A gentamicin pharmacokinetic population model and once-daily dosing algorithm for neonates. Pharmacotherapy (2003) 0.95
Indinavir, efavirenz, and abacavir pharmacokinetics in human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2003) 0.95
Effect of fluoroquinolone expenditures on susceptibility of Pseudomonas aeruginosa to ciprofloxacin in U.S. hospitals. Am J Health Syst Pharm (2003) 0.95
Front-loaded linezolid regimens result in increased killing and suppression of the accessory gene regulator system of Staphylococcus aureus. Antimicrob Agents Chemother (2012) 0.93
Pharmacokinetic drug interactions with non-nucleoside reverse transcriptase inhibitors. Expert Opin Drug Metab Toxicol (2005) 0.93
The outcomes of emergency pharmacist participation during acute myocardial infarction. J Emerg Med (2010) 0.93
Functionally Distinct Subpopulations of CpG-Activated Memory B Cells. Sci Rep (2012) 0.93
Renal substrate exchange and gluconeogenesis in normal postabsorptive humans. Am J Physiol Endocrinol Metab (2002) 0.92
Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection. Antimicrob Agents Chemother (2009) 0.92
The influence of St. John's wort on the pharmacokinetics and protein binding of imatinib mesylate. Pharmacotherapy (2004) 0.91
Regulation of RUNX2 transcription factor-DNA interactions and cell proliferation by vitamin D3 (cholecalciferol) prohormone activity. J Bone Miner Res (2012) 0.91
Prevalence of platelet nonresponsiveness to aspirin in patients treated for secondary stroke prophylaxis and in patients with recurrent ischemic events. J Clin Pharmacol (2008) 0.91
Pharmacokinetic modelling of efavirenz, atazanavir, lamivudine and tenofovir in the female genital tract of HIV-infected pre-menopausal women. Clin Pharmacokinet (2012) 0.91
Population pharmacokinetics of ceftaroline in patients with acute bacterial skin and skin structure infections or community-acquired bacterial pneumonia. J Clin Pharmacol (2013) 0.91
Effect of myostatin depletion on weight gain, hyperglycemia, and hepatic steatosis during five months of high-fat feeding in mice. PLoS One (2011) 0.90
Pharmacokinetics and pharmacodynamics of enoxaparin in multiple trauma patients. J Trauma (2005) 0.89
Higher activity of polymorphic NAD(P)H:quinone oxidoreductase in liver cytosols from blacks compared to whites. Toxicol Lett (2006) 0.89
Evaluation of lacrimal fluid as an alternative for monitoring glucose in critically ill patients. Intensive Care Med (2005) 0.89
Pharmacokinetics-pharmacodynamics of tigecycline in patients with community-acquired pneumonia. Antimicrob Agents Chemother (2011) 0.88
Evaluating ciprofloxacin dosing for Pseudomonas aeruginosa infection by using clinical outcome-based Monte Carlo simulations. Antimicrob Agents Chemother (2005) 0.88
Coadministration of milk thistle and indinavir in healthy subjects. Pharmacotherapy (2003) 0.88
Pharmacodynamics of early, high-dose linezolid against vancomycin-resistant enterococci with elevated MICs and pre-existing genetic mutations. J Antimicrob Chemother (2012) 0.87
Multiple nuclear gene phylogenetic analysis of the evolution of dioecy and sex chromosomes in the genus Silene. PLoS One (2011) 0.87
Predictors of agr dysfunction in methicillin-resistant Staphylococcus aureus (MRSA) isolates among patients with MRSA bloodstream infections. Antimicrob Agents Chemother (2011) 0.87
Multidrug resistance 1 polymorphisms and trough concentrations of atazanavir and lopinavir in patients with HIV. Pharmacogenomics (2007) 0.86
Polymyxin combinations: pharmacokinetics and pharmacodynamics for rationale use. Pharmacotherapy (2015) 0.86
Population exposure-response modeling of metformin in patients with type 2 diabetes mellitus. J Clin Pharmacol (2008) 0.86
Pharmacokinetics-pharmacodynamics of gatifloxacin in a lethal murine Bacillus anthracis inhalation infection model. Antimicrob Agents Chemother (2007) 0.86
Chromosome 5 monosomy of Candida albicans controls susceptibility to various toxic agents, including major antifungals. Antimicrob Agents Chemother (2013) 0.86
SPLINDID: a semi-parametric, model-based method for obtaining transcription rates and gene regulation parameters from genomic and proteomic expression profiles. Bioinformatics (2005) 0.85
Relative importance of liver, kidney, and substrates in epinephrine-induced increased gluconeogenesis in humans. Am J Physiol Endocrinol Metab (2003) 0.84
Cytochrome P450 3A4 activity after surgical stress. Crit Care Med (2003) 0.84
Population pharmacokinetics of fusidic acid: rationale for front-loaded dosing regimens due to autoinhibition of clearance. Antimicrob Agents Chemother (2012) 0.84
Evaluation of the pharmacokinetics-pharmacodynamics of fusidic acid against Staphylococcus aureus and Streptococcus pyogenes using in vitro infection models: implications for dose selection. Diagn Microbiol Infect Dis (2011) 0.84
Pharmacokinetic-pharmacodynamic analyses for efficacy of ceftaroline fosamil in patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother (2013) 0.83
Considering CYP1A2 phenotype and genotype for optimizing the dose of olanzapine in the management of schizophrenia. Expert Opin Drug Metab Toxicol (2013) 0.83
The clinical impact of 1:1 conversion from Neoral to a generic cyclosporine (Gengraf) in renal transplant recipients with stable graft function. Clin Transplant (2006) 0.83
Pharmacokinetics of indinavir and nelfinavir in treatment-naive, human immunodeficiency virus-infected subjects. Antimicrob Agents Chemother (2004) 0.83
Analysis of omeprazole, midazolam and hydroxy-metabolites in plasma using liquid chromatography coupled to tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci (2005) 0.83